An Open-label, Single Dose Study to Evaluate Lemborexant in Milk of Healthy Lactating Women
Latest Information Update: 07 Sep 2021
At a glance
- Drugs Lemborexant (Primary)
- Indications Chronic obstructive pulmonary disease; Circadian rhythm sleep disorders; Insomnia; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 02 Sep 2021 Status changed from recruiting to completed.
- 27 May 2021 Status changed from not yet recruiting to recruiting.
- 20 May 2021 New trial record